NCCN Guidelines® Updates: Management of Multiple Myeloma
This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Multiple Myeloma, Version 3.2018
The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, evaluation, treatment, including supportive care, and follow-up for patients with myeloma.
Category
  • Multiple Myeloma
Format
  • Monograph/Journal Supplement
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Integrating New Treatment Options for Multiple Myeloma: Focus on Oral Therapies
Join Richard L. Fong, PharmD, BCOP from UCSF Helen Diller Family Comprehensive Cancer Center for this webinar in the 2018 NCCN Pharmacy Update Webinar Series on the topic Integrating New Treatment Options for Multiple Myeloma: Focus on Oral Therapies.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms
Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Current Approaches to Initial Treatment of Newly Diagnosed Multiple Myeloma
The number of treatment options for both transplant eligible and transplant ineligible patients continues to grow year after year.  Regimens previously approved in the second-line setting are proving to be efficacious as primary therapy.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Emerging Options and Sequencing Therapies for Relapsed Multiple Myeloma
Promising clinical responses have even been seen in heavily pretreated patients, suggesting that the new therapeutic options benefit those who have exhausted all traditional lines of therapy.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
CAR T-Cell Therapy: Recent Advances and Future Considerations
Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options.
Category
  • Acute Lymphoblastic Leukemia
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation